Neurology Central

ALKS 5461 accepted for review following previous refusal-to-file for depression: industry news round-up

0
In this week’s industry news round-up, we’ve chosen the latest updates from a wide range of disorders extending from depression to multiple sclerosis. Find out more about our selection of the highlights below.
Our pick of the headlines include:
  • ALKS 5461 accepted for review following previous refusal-to-file for depression
  • Aimovig® halves migraine days in late-stage study, heading towards possible May approval
  • Biogen and Ionis in 10-year collaboration to develop novel drug candidates for neurological diseases
  • Novartis to seek FDA approval after additional Phase III data for siponimod in SPMS announced
    Restricted Content / Members Only

    You cannot view this content because It is available to members only. Please or Register to view this area.

Share:

Leave A Comment